s100p

S100P-IN-1 is a potent S100P inhibitor.S100P-IN-1 has anti-metastatic effects on pancreatic cancer (pancreatic) cells.

Amlexanox (AA673) is an anti-aphthous ulcer drug. Amlexanox inhibits the synthesis and release of inflammatory mediators, including leukotrienes and histamine, from mast cells, neutrophils, and mononuclear cells. Amlexanox also acts as a leukotriene D4 antagonist and a phosphodiesterase inhibitor. Amlexanox decreases the time ulcers take to heal as well as the pain associated with the ulcers.

Cromolyn sodium (FPL-670) is a chromone complex that acts by inhibiting the release of chemical mediators from sensitized mast cells.

5-Methyl cromolyn (C5OH) disodium is a cromolyn analog that acts as an S100P inhibitor. It prevents the interaction between S100P and its receptor RAGE, hinders NF-κB activity and cell proliferation, and enhances apoptosis induced by Gemcitabine. In murine models with PDAC, 5-Methyl cromolyn disodium reduces tumor growth and metastasis, thereby extending survival. This compound is suitable for pancreatic cancer research, including studies on pancreatic ductal adenocarcinoma (PDAC).

Receptor for advanced glycation end products (RAGE) antagonist. Blocks S100P, S100A4 and HMGB-1 mediated RAGE activation in vitro and in vivo. Inhibits growth and metastasis of rat glioma tumors. Reduces cell growth and RAGE-mediated NF-κB activity in hum

RAGE antagonist peptide acetate is an advanced antagonist of glycation end products (RAGE). RAGE antagonist peptide acetate possesses anti-tumor and anti-inflammatory activities. RAGE antagonist peptide acetate prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4.